Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Insulin-Treated Diabetes with Hypercholesterolemia
NCT02585778Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Oct 2015; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02585778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585778.